Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24⁺ patients with renal cell carcinoma

详细信息    查看全文

• 作者：Takafumi Minami^a ; ^{minami@med.kindai.ac.jp} ; Naoki Matsumura^a ; Koichi Sugimoto^a ; Nobutaka Shimizu^a ; Marco De Velasco^a ; Masahiro Nozawa^a ; Kazuhiro Yoshimura^a ; Nanae Harashima^b ; Mamoru Harada^b ; Hirotsugu Uemura^a ; ^{huemura@med.kindai.ac.jp}
• 关键词：HIFs ; hypoxia-inducing factors ; RCC ; renal cell carcinoma ; VHL ; von Hippel-Lindau ; CTLs ; cytotoxic T lymphocytes ; mRCC ; metastatic renal cell carcinoma ; IL ; interleukin ; IFN ; interferon ; PD-1 ; programmed cell death-1 ; PD-L1 ; PD-ligand-1 ; CTLA-4 ; cytotoxic T-lymphocyte-associated protein-4 ; CA ; carbonic anhydrase ; PBMCs ; peripheral blood mononuclear cells ; HDs ; healthy donors ; HIV ; human immunodeficiency virus ; EBV ; EPSTEIN-Barr virus ; DFO ; desferrioxamine
• 刊名：International Immunopharmacology
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：44
• 期：Complete
• 页码：197-202
• 全文大小：526 K
• 卷排序：44

文摘

Renal cell carcinoma (RCC) is often associated with von Hippel-Lindau (VHL) gene mutations, leading to up-regulation of HIFs. From a different point of view, this suggests the possibility that HIFs could be promising targets in anti-cancer therapy. We identified a HIF-1α 278-287 peptide as a candidate of anti-cancer vaccine for HLA-A24+ RCC patients.